We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Esophageal Stent Alleviates Benign Strictures

By HospiMedica International staff writers
Posted on 06 Mar 2014
Image: The WallFlex Nitinol esophageal stent (Photo courtesy of Boston Scientific).
Image: The WallFlex Nitinol esophageal stent (Photo courtesy of Boston Scientific).
A fully covered metal stent provides new treatment options for patients with benign narrowing of the esophagus.

The WallFlex esophageal stent is made of a nickel-titanium (Nitinol) wire braided construction that provides luminal patency in the presence of strictures or benign tumors. The stent is designed for gradual expansion, typically complete in 24-72 hours; it features a Permalume silicone coating that is designed to prevent tumor in-growth, seal concurrent esophageal fistulas, and help reduce food impaction. The WallFlex Stent also provides physicians with clear visualization during fluoroscopy, aiding in accurate placement, as well as progressive, step flared ends that assist in anchoring the stent within the esophageal lumen.

An additional feature is a Teflon coated polyester suture that enables easy removal for up to eight weeks, potentially saving patients from having to visit the hospital to undergo additional dilations. The WallFlex Esophageal Fully Covered Stent is a product of Boston Scientific (Natick, MA, USA), and has received the European Community CE marking of approval. The stent is not approved for the removal from malignant strictures and has not been approved in the United States for the treatment of refractory benign esophageal strictures.

“Building on the best of Boston Scientific's industry-leading stents, the expanded indication for the WallFlex Esophageal Fully Covered Stent demonstrates our commitment to physician needs and dedication to improving patient outcomes,” said David Pierce, president of endoscopy at Boston Scientific. “This enables physicians in the European Union to provide additional options for the treatment and management of patients suffering from benign esophageal strictures.”

“Fully covered esophageal stents are a valid therapeutic option in patients with benign refractory esophageal strictures,” said Javier Jimenez, MD, chief of the Endoscopy Department at Complejo Hospitalario de Navarra (Pamplona, Spain). “I use the WallFlex Esophageal Stent because its small profile and radiopacity facilitate accurate placement, the migration rate is low, and stent removal is usually easy.”

Benign esophageal strictures are a narrowing or tightening of the esophagus caused by scarring that cause swallowing difficulties. Strictures can be caused by or associated with gastroesophageal reflux disease (GERD), esophagitis, a dysfunctional lower esophageal sphincter, disordered motility, lye ingestion, or a hiatal hernia. Strictures can also form after esophageal surgery and other treatments such as laser therapy or photodynamic therapy (PDT). The primary treatment is dilation of the esophagus, which may need to be repeated after a period if the stricture recurs.

Related Links:

Boston Scientific


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
High-Precision QA Tool
DEXA Phantom
New
Hospital Data Analytics App
Alarm History Analytics

Channels

Critical Care

view channel
The intelligent wound dressing consists of a granular hydrogel (Photo courtesy of Apoorv Singh/ETH Zurich)

Intelligent Wound Dressing Reduces Inflammation and Promotes Healing

Chronic wounds, especially those caused by diabetes or circulatory disorders, are a widespread medical problem that burden healthcare systems. Patients often suffer from open skin lesions that fail to... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more